A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women



Status:Completed
Conditions:HIV / AIDS, Women's Studies
Therapuetic Areas:Immunology / Infectious Diseases, Reproductive
Healthy:No
Age Range:18 - Any
Updated:7/8/2018
Start Date:April 9, 2009
End Date:August 11, 2016

Use our guide to learn which trials are right for you!

A Single Arm, Open Label Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

The purpose of this study is to study how changes in the body during pregnancy influence the
blood levels of TMC114 (darunavir) and ritonavir taken together, darunavir and cobicistat
taken as a fixed-dose combination, TMC125 (etravirine) taken alone or with darunavir and
ritonavir or rilpivirine in patients with human immunodeficiency virus-1 (HIV-1). This study
will examine how these drugs are absorbed in the body, how they are distributed within the
body and how they are removed from the body over time. Any pregnant woman who is currently
receiving darunavir with ritonavir, darunavir with cobicistat, etravirine or rilpivirine for
HIV-1, and who meets the eligibility criteria for the study, will be allowed to enroll.
Patients must be willing to remain on study medication during the course of their pregnancy,
and 12 weeks postpartum. The information collected may help answer questions about how to
best prescribe these three drugs for pregnant women.

There are many biological changes that occur during pregnancy, some of which may affect the
way HIV medications are absorbed, distributed and removed within the body. Some medications
have been used for HIV treatment during pregnancy, but little is known about how pregnancy
affects the class of drugs being used in this study. To participate in this study, patients
must be receiving 600mg of TMC114 (darunavir) taken with 100mg ritonavir twice daily or 800mg
of TMC114 (darunavir) with 100mg of ritonavir once daily or 800 mg of darunavir taken with
150mg of cobicistat taken once daily or 200mg of TMC125 (etravirine) (with or without
darunavir/ ritonavir) taken twice daily or 25mg of TMC278 (rilpivirine) taken once daily plus
additional antiretroviral drugs needed to construct an active antiretroviral regimen.
Darunavir and ritonavir, darunavir and cobicistat, etravirine, or rilpivirine will be
supplied to study participants. Darunavir and ritonavir are human immunodeficiency virus
(HIV) protease inhibitors (PIs); cobicistat is a pharmacoenhancer which boosts the levels of
darunavir but has no anti-HIV activity; etravirine and rilpivirine are non-nucleoside reverse
transcriptase inhibitor (NNRTI) of HIV. Twelve-hour or twenty four-hour blood sampling will
be done for each patient at each of three study visits: Visit 4 (2nd trimester), Visit 5 (3rd
trimester), and Visit 8 (6-12 weeks postpartum). Eight blood draws will be taken during each
visit: One prior to intake of study medication, and one for each of seven post-dose sampling
time-points (hours 1, 2, 3, 4, 6, 9 and 12). The study is designed primarily to examine the
pharmacokinetics of darunavir/ritonavir (darunavir/r), darunavir/ cobicistat, etravirine or
rilpivirine during the second and third trimesters of gestation, as well as postpartum.
Pharmacokinetics measures how the body absorbs, distributes and excretes medication. The
study will also examine any changes in anti-viral activity during pregnancy, and the
postpartum period. It will note any safety and tolerability of the medications used by the
mother, and will measure the level of darunavir/ritonavir, darunavir/ cobicistat, etravirine
or rilpivirine in the newborn's cord blood at the time of delivery; outcomes for both mother
and child will be assessed as well. During the treatment period, patients will be seen at
regular visits in the clinic, where the investigator will assess the patient's medical
condition, any Adverse Events and study drug compliance. Laboratory evaluations for efficacy
and safety will be done at regular visits as well as blood pressure monitoring. Up to
forty-eight (48) HIV positive pregnant women will participate in this study. Study enrollment
will be closed once 12 evaluable patients taking darunavir/ritonavir once daily, 12 evaluable
patients taking darunavir/cobicistat once daily, 12 evaluable patients taking
darunavir/ritonavir twice daily, 12 evaluable patients taking etravirine taking twice daily
and 12 evaluable patients taking rilpivirine once daily have been enrolled. The study will be
conducted at approximately 14 research centers in the United States and 1 in Puerto Rico. In
order to participate, patients must be pregnant for 13-24 weeks. The primary purpose (or
outcome) of the study is to assess the influence of pregnancy on the pharmacokinetics of
darunavir/ritonavir, darunavir/ cobicistat, etravirine or rilpivirine during the second and
third trimesters of gestation, as well as postpartum. Darunavir: One 600 mg or two 300 mg
tablets taken twice daily by mouth (two or four tablets a day total). Ritonavir: 100mg tablet
taken twice daily by mouth (two tablets a day total), together with darunavir. Darunavir: Two
400 mg tablets taken once daily by mouth (two tablets a day total). Ritonavir: 100mg tablet
taken once daily by mouth (one tablet a day total), together with darunavir. Darunavir/
cobicistat: a fixed dose combination containing 800mg of darunavir and 150mg of cobicistat.
Etravirine: Two 100 mg tablets taken twice daily by mouth (four tablets a day total).
Rilpivirine: One 25mg tablet taken once daily by mouth (one tablet a day total). Study
medication will be given from the baseline visit (second pregnancy trimester) until Visit 8
(up to 12 weeks after delivery).

Inclusion Criteria:

- Pregnant females (18-26 weeks of gestation)

- documented HIV-1 infection

- Receiving darunavir/ritonavir, darunavir/cobicistat, etravirine, or rilpivirine at the
time of study entry

- Willing to remain on darunavir/ritonavir, darunavir/cobicistat, etravirine, or
rilpivirine as well as a background regimen, for the duration of the study, including
12 weeks postpartum

- Able to comply with the protocol requirements and to provide written informed consent.

Exclusion Criteria:

- Patients with any currently active acquired immune deficiency syndrome (AIDS) defining
illness and AIDS-related opportunistic infection

- Patients using cytokine inhibitors (e.g., thalidomide), anabolic hormones, cytokines
(e.g., IL-2, INF), efavirenz, hydroxyurea, oral hypoglycemics, systemic chemotherapy
or known teratogenic agent

- Use of an investigational agent within 90 days

- Any known fetal anomaly

- Any current obstetric complication, including multiple gestations and pre-term labor

- Hepatitis B and/or C virus infection

- Grade 2 or higher anemia

- Thyroid disease

- Uncontrolled Diabetes Mellitus Types I and II, or gestational diabetes, as determined
by the investigator
We found this trial at
17
sites
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
?
mi
from
Bellaire, TX
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
?
mi
from
Dearborn, MI
Click here to add this to my saved trials
Greensboro, North Carolina 27401
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
Pensacola, FL
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
?
mi
from
San Juan Pr,
Click here to add this to my saved trials
?
mi
from
Savannah, GA
Click here to add this to my saved trials
Springfield, Massachusetts 01199
?
mi
from
Springfield, MA
Click here to add this to my saved trials
?
mi
from
Syracuse, NY
Click here to add this to my saved trials